Disruption of Rb/E2F pathway results in increased cyclooxygenase-2 expression and activity in prostate epithelial cells

Cancer Research

Volumn 65, Issue 9, 2005, Pages 3633-3642

  Davis, Joanne N ^a   McCabe, Michael T ^a   Hayward, Simon W ^b   Park, John M ^a   Day, Mark L ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1;

ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA BINDING; DYSPLASIA; ENZYME ACTIVITY; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ONCOGENE C MYB; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN DOMAIN; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; UPREGULATION; WILD TYPE;

ANIMALS; CELL CYCLE PROTEINS; CELL LINE; CYCLOOXYGENASE 2; DINOPROSTONE; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; ENZYME ACTIVATION; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, MYC; MALE; MICE; PROMOTER REGIONS (GENETICS); PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATE; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 18144413915     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3129     Document Type: Article

References (53)

1. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-82.
2. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
3. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-9.
4. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
5. Nagai N, Tian X, Mukai K, et al. Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neo-adjuvant chemotherapy. Int J Mol Med 2003;12:709-14.
6. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-60.
7. Fujita H, Koshida K, Keller ET, et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2002;53:232-40.
8. Oshima M, Dinchuk JE, Kargman SL, et al, Suppression of intestinal polyposis in Apc δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
9. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000;60:4705-8.
10. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73-8.
11. Yoshimura R, Sano H, Masuda C, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89:589-96.
12. Madaan S, Abel PD, Chaudhary KS, et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 2000;86:736-41.
13. Zha S, Gage WR, Sauvageot J, et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61:8617-23.
14. Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-α in normal and malignant prostate cells. Cancer Res 2001;61:2720-6.
15. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 2004;61;60-72.
16. Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004;64:3334-43.
17. Shappell SB, Olson SJ, Hannah SE, et al. Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Cancer Res 2003;63:2256-67.
18. Phillips SM, Morton DG, Lee SJ, Wallace DM, Neoptolemos JP. Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Br J Urol 1994:73:390-5.
19. Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjanen K. Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival. Eur J Cancer 1995;31A:329-33.
20. Gope R, Gope ML. Abundance and state of phosphorylation of the retinoblastoma susceptibility gene product in human colon cancer. Mol Cell Biochem 1992;110:123-33.
21. Primdahl H, von der Maase H, Christensen M, Wolf H, Orntoft TF. Allelic deletions of cell growth regulators during progression of bladder cancer. Cancer Res 2000;60:6623-9.
22. Nevins JR. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ 1998;9:585-93.
23. Sherr CJ. Cancer cell cycles. Science 1996;274:I672-7.
24. Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG. Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci U S A 1998;95:8858-63.
25. Pierce AM, Schneider-Broussard R, Gimenez-Conti IB, Russell JL, Conti CJ, Johnson DG. E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Mol Cell Biol 1999;19:6408-14.
26. Pierce AM, Fisher SM, Conti CJ, Johnson DG. Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development. Oncogene 1998;16:1267-76.
27. Zhang SY, Liu SC, Johnson DG, Klein-Szanto AJ. E2F-1 gene transfer enhances invasiveness of human head and neck carcinoma cell lines. Cancer Res 2000;60:5972-6.
28. Zhang SY, Liu SC, Al-Saleem LF, et al. E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev 2000:9:395-401.
29. Gorgoulis VG, Zacharatos P, Mariatos G, et al. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 2002;198:142-56.
30. Etges A, Nunes FD, Ribeiro KC, Araujo VC. Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours. Oral Oncol 2004;40:326-31.
31. Ma Y, Croxton R, Moorer RL Jr, Cress WD. Identification of novel E2F1-regulated genes hy micro-array. Arch Biochem Biophys 2002;399:212-24.
32. Day KC, McCabe MT, Zhao X, et al. Rescue of embryonic epithelium reveals that the homozygous deletion of the retinoblastoma gene confers growth factor independence and immortality but does not influence epithelial differentiation or tissue morphogenesis. J Biol Chem 2002;277:44475-84.
33. Wang Y, Hayward SW, Donjacour AA, et al. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res 2000;60:6008-17.
34. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-9.
35. 2 in human prostatic carcinoma cells. Br J Cancer 1997;75:1111-8.
36. Liu XH, Kirschenbaum A, Lu M, et al. Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem Biophys Res Commun 2002;290:249-55.
37. Macleod KF, Hu Y, Jacks T. Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO J 1996;15:6178-88.
38. Ruiz S, Santos M, Segrelles C, et al. Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development 2004;131:2737-48.
39. Neuman E, Flemington EK, Sellers WR, Kaelin WG Jr. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol Cell Biol 1994;14:6607-15.
40. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003;424:223-8.
41. Black EP, Huang E, Dressman H, et al. Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res 2003;63:3716-23.
42. Ishida S, Huang E, Zuzan H, et al. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 2001;21:4684-99.
43. Ramsay RG, Friend A, Vizantios Y, et al. Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB. Cancer Res 2000;60:1805-9.
44. Sala A, Nicolaides NC, Engelhard A, et al. Correlation between E2F-1 requirement in the S phase and E2F-1 transactivation of cell cycle-related genes in human cells. Cancer Res 1994;54:1402-6.
45. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-403.
46. Nikolic D, van Breemen RB. DNA oxidation induced hy cyclooxygenase-2. Chem Res Toxicol 2001;14:351-4.
47. Leung WK, To KF, Go MY, et al. Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int J Oncol 2003;23:1317-22.
48. Crawford YG, Gauthier ML, Joubel A, et al. Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. Cancer Cell 2004;5:263-73.
49. Hurford RK Jr, Cobrinik D, Lee MH, Dyson N. pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev 1997;11:1447-63.
50. Campanero MR, Armstrong M, Flemington E. Distinct cellular factors regulate the c-myb promoter through its E2F element. Mol Cell Biol 1999;19:8442-50.
51. Slamon DJ, Boone TC, Murdock DC, et al. Studies of the human c-myb gene and its product in human acute leukemias. Science 1986;233:347-51.
52. Griffin CA, Baylin SB. Expression of the c-myb oncogene in human small cell lung carcinoma. Cancer Res 1985;45:272-5.
53. Alitalo K, Winqvist R, Lin CC, de la Chapelle A, Schwab M, Bishop JM. Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma. Proc Natl Acad Sci U S A 1984;81:4534-8.